Adverum Biotechnologies, Inc. (ADVM)
NASDAQ: ADVM · Real-Time Price · USD
4.740
+0.040 (0.85%)
Dec 20, 2024, 4:00 PM EST - Market closed
Adverum Biotechnologies Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 1 | 3.6 | - | 7.5 | - | 0.25 | |
| Revenue Growth (YoY) | -72.22% | - | - | - | - | -84.49% | |
| Cost of Revenue | 68.22 | 77.68 | 95.58 | 89.18 | 73.31 | 40.42 | |
| Gross Profit | -67.22 | -74.08 | -95.58 | -81.68 | -73.31 | -40.17 | |
| Selling, General & Admin | 35.65 | 49.69 | 54.73 | 63.38 | 44.64 | 28.38 | |
| Operating Expenses | 35.65 | 49.69 | 54.73 | 63.38 | 44.64 | 28.38 | |
| Operating Income | -102.88 | -123.77 | -150.31 | -145.06 | -117.95 | -68.55 | |
| Interest & Investment Income | 7.86 | 5.75 | 2.67 | 0.58 | 1.56 | 4.06 | |
| EBT Excluding Unusual Items | -95.02 | -118.02 | -147.64 | -144.48 | -116.39 | -64.49 | |
| Merger & Restructuring Charges | - | - | -4.7 | - | - | - | |
| Asset Writedown | -0.22 | -0.22 | -2.12 | -1.06 | - | - | |
| Pretax Income | -95.24 | -118.24 | -154.46 | -145.54 | -116.39 | -64.49 | |
| Income Tax Expense | -1.13 | -1.08 | 0.07 | - | 1.11 | - | |
| Net Income | -94.11 | -117.17 | -154.54 | -145.54 | -117.51 | -64.49 | |
| Net Income to Common | -94.11 | -117.17 | -154.54 | -145.54 | -117.51 | -64.49 | |
| Shares Outstanding (Basic) | 17 | 10 | 10 | 10 | 9 | 6 | |
| Shares Outstanding (Diluted) | 17 | 10 | 10 | 10 | 9 | 6 | |
| Shares Change (YoY) | 70.02% | 1.58% | 1.24% | 15.14% | 32.83% | 4.44% | |
| EPS (Basic) | -5.51 | -11.62 | -15.57 | -14.85 | -13.80 | -10.06 | |
| EPS (Diluted) | -5.51 | -11.62 | -15.57 | -14.85 | -13.80 | -10.06 | |
| Free Cash Flow | -86.06 | -91.71 | -119.91 | -122.95 | -91.14 | -68.42 | |
| Free Cash Flow Per Share | -5.04 | -9.10 | -12.08 | -12.54 | -10.70 | -10.67 | |
| Operating Margin | -10287.60% | -3437.97% | - | -1934.12% | - | -27418.00% | |
| Profit Margin | -9411.10% | -3254.58% | - | -1940.53% | - | -25794.40% | |
| Free Cash Flow Margin | -8606.00% | -2547.50% | - | -1639.39% | - | -27366.80% | |
| EBITDA | -99.02 | -118.12 | -143.78 | -140.41 | -113.79 | -66.97 | |
| D&A For EBITDA | 3.85 | 5.64 | 6.53 | 4.65 | 4.16 | 1.57 | |
| EBIT | -102.88 | -123.77 | -150.31 | -145.06 | -117.95 | -68.55 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.